Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
about
Aptamers: A Feasible Technology in Cancer ImmunotherapyToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsTargeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.B7-H3 role in the immune landscape of cancer.Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanomaAnalyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.Thyroid dysfunctions secondary to cancer immunotherapy.Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.Targeted therapy of brain metastases: latest evidence and clinical implications.Immune checkpoint pathways in non-small cell lung cancer.Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Melanoma treatment in review.A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer.Immunotherapies: Exploiting the Immune System for Cancer Treatment.The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-DependentDeep Learning in Drug Discovery and Medicine; Scratching the Surface
P2860
Q26740303-49E655DC-3B05-4737-89C9-66EDA7EA01E3Q28067583-08795C68-BF03-41B4-A15A-A3961C73E59AQ33728298-12F815FA-31DD-41A6-A4C0-EB4A8FB8D5F7Q34550012-157078E8-4103-4424-8890-0A4CA8C3242EQ35933820-4785C875-61B9-444A-9D3F-5E62113DA2F0Q37675967-0EF4DB9A-36FB-4FE7-8F4F-A7E7448C5475Q39427326-BEEFEC8B-EE29-4A6F-93E1-8A83F8D2DF01Q42066160-CB0B788E-B31C-4147-AD47-376D386AC4CBQ42188216-8BF27E49-B645-4701-AB96-5EEB7855738DQ47105622-D5E38A9B-3F99-41EF-AE1D-607462011F62Q47565857-55E414AC-D4F4-486D-8E0E-6E9D88B79E9AQ47665473-7AC70466-28D1-438A-A6D6-8CAC22233377Q49956245-08F0FDDF-D40A-49C2-8E34-FC465A729BF3Q52581741-C6F28A02-7F29-412F-9DA1-128AA9D39B88Q52603540-FBFCA130-EE32-4F73-BA96-7DB74BB29973Q53068034-46748D4F-8304-4B52-8FAC-0D20CB400064Q55217220-D1C436AD-1134-43D5-BF45-8209A17B2E04Q55263175-9FC632B8-F565-4E26-8FBB-26D38E9554C1Q55362851-8CB96E7A-D375-43C1-9A44-BF5E9D3E6F5EQ57816676-1E380D30-C5DA-4E99-B441-B84813521008Q58691544-A7453731-62A5-4995-BE31-A46CBA8D5B36
P2860
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@ast
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@en
type
label
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@ast
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@en
prefLabel
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@ast
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@en
P2860
P1476
Opdivo (Nivolumab): Second PD- ...... ectable or Metastatic Melanoma
@en
P2093
Lisa A Raedler
P2860
P304
P433
Spec Feature
P577
2015-03-01T00:00:00Z